New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 8, 2014
09:23 EDTHPTXHyperion Therapeutics should be bought on any weakness, says JMP Securities
After sales of Hyperion's Ravicti beat expectations in Q2 but the company disclosed a delay in the initiation of its planned Phase 3 hepatic encephalopathy program for Ravicti, JMP Securities thinks any weakness in the stock is a buying opportunity for investors with a long-term focus, and/or an appreciation for the potential value of the company's diabetes program. The firm notes that Phase 3 data for the drug is expected in 1Q15 and keeps an Outperform rating.
News For HPTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 4, 2015
10:19 EDTHPTXHyperion Therapeutics management to meet with Needham
Subscribe for More Information
February 27, 2015
07:20 EDTHPTXHyperion Therapeutics could be a takeout target, says Brean Capital
Subscribe for More Information
February 26, 2015
16:38 EDTHPTXHyperion Therapeutics sees 2015 revenue $120M-$128M, consensus $119.3M
Subscribe for More Information
16:38 EDTHPTXHyperion Therapeutics reports Q4 adjusted EPS 47c
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use